Anacetrapib

Quality 0.50 · 1 view · Updated 2 months ago

title: "Anacetrapib" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["trifluoromethyl-compounds", "2-oxazolidinones", "o-methylated-phenols", "experimental-drugs", "fluoroarenes", "isopropyl-compounds", "abandoned-drugs", "cetp-inhibitors"] topic_path: "arts/music" source: "https://en.wikipedia.org/wiki/Anacetrapib" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

| Verifiedfields = changed | verifiedrevid = 444391072 | ImageFile = Anacetrapib.svg | ImageClass = skin-invert-image | ImageSize = 200px | PIN = (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-{[4′-fluoro-2′-methoxy-5′-(propan-2-yl)-4-(trifluoromethyl)[1,1′-biphenyl]-2-yl]methyl}-4-methyl-1,3-oxazolidin-2-one | OtherNames = MK-0859 |Section1={{Chembox Identifiers | ChemSpiderID_Ref = | ChemSpiderID = 9731205 | InChI = 1/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1 | InChIKey = MZZLGJHLQGUVPN-HAWMADMCBN | StdInChI_Ref = | StdInChI = 1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1 | StdInChIKey_Ref = | StdInChIKey = MZZLGJHLQGUVPN-HAWMADMCSA-N | UNII_Ref = | UNII = P7T269PR6S | CASNo_Ref = | CASNo = 875446-37-0 | PubChem = 11556427 | ChEMBL_Ref = | ChEMBL = 1800807 | KEGG_Ref = | KEGG = D08855 | SMILES = O=C2OC@HC@@HC |Section2={{Chembox Properties | Formula = C30H25F10NO3 | MolarMass = 637.51 g·mol−1 | Appearance = | Density = | MeltingPt = | BoilingPt = | Solubility = |Section3={{Chembox Hazards | MainHazards = | FlashPt = | AutoignitionPt = Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease. |vauthors =Gutstein DE, Krishna R, Johns D |title=Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction |journal=Clinical Pharmacology & Therapeutics |volume=91 |issue=1 |pages=109–122 |year=2012 |doi=10.1038/clpt.2011.271 |pmid=22130116 |s2cid=36510986 |url=http://www.nature.com/clpt/journal/v91/n1/full/clpt2011271a.html | display-authors=etal|url-access=subscription

Evidence

In 2017 REVEAL trial anacetrapib was shown to decrease the risk of repeat heart attacks in high-risk patients with previous acute coronary events.

References

References

  1. (2017). "Merck says will not seek approval of cholesterol treatment". Reuters.
  2. (29 September 2017). "Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?". Diseases.

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::

trifluoromethyl-compounds2-oxazolidinoneso-methylated-phenolsexperimental-drugsfluoroarenesisopropyl-compoundsabandoned-drugscetp-inhibitors